Key result
CKD is linked to ~11-fold higher plasma cystatin C levels that increase linearly with disease severity.
Why the study?
Chronic kidney disease is an increasingly common global health problem, especially in Vietnam, and this study aimed to estimate cystatin C concentrations and variation across different CKD stages.
Are plasma cystatin C levels elevated in patients with chronic kidney disease compared to healthy individuals?
Cross-Sectional (n=177)
No
Are plasma cystatin C levels elevated in patients with chronic kidney disease compared to healthy individuals?
Absolute Event Rate: 9.17% vs 0.82%
p-value: p=<0.001
Plasma cystatin C is significantly elevated in patients with chronic kidney disease and correlates with disease severity, serving as an effective marker for kidney damage.
Cystatin C may aid CKD assessment; leaves open incremental value over creatinine in prospective cohorts.
Background: Chronic kidney disease (CKD) is an increasingly common disease worldwide and has become a global health problem, especially in Vietnam. Cystatin C is a marker for the detection, classification, and prognosis of CKD. Cystatin C is filtered entirely through the glomerular membrane, reabsorbed, and metabolized completely in the renal tubules. In case of damage to the kidneys, glomerular filtration rate declines, and some substances increase in the blood, such as cystatin C. The concentration of cystatin C changes with damage to the renal system. Objectives: This study aimed to estimate the concentration of cystatin C and its variation in the different stages of CKD. Methods: A descriptive, cross-sectional study was conducted on 40 healthy individuals and 137 patients with CKD grade III, IV, and V in 103 Hospital. The concentration of cystatin C was estimated in all subjects. Results: Cystatin C plasma levels were significantly higher in the CKD group (9.17 ± 3.75 mg/L) than in the control group (0.82 ± 0.12 mg/L). Cystatin C plasma levels increased linearly with the serious kidney failure as the stage of CKD. Conclusions: Cystatin C is an effective marker for estimating kidney damage in CKD.
No takes yet. Share an insight, caveat, or question.
Văn et al. (2022) conducted a cross-sectional in Chronic Kidney Disease (n=177). Chronic Kidney Disease vs. Healthy controls was evaluated on Plasma Cystatin C level (mg/L) (p=<0.001). Plasma cystatin C levels were significantly higher in patients with chronic kidney disease compared to healthy controls (9.17 mg/L vs 0.82 mg/L, p<0.001) and increased linearly with disease severity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: